The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Reasons for treatment discontinuation in multiple myeloma: insights from the PREAMBLE registry
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, presents real-world findings from the prospective PREAMBLE study (NCT01838512) assessing rates and reasons for treatment discontinuation in patients with multiple myeloma (MM). The data indicated that discontinuation rates are high in the real-world setting, driven primarily by treatment fatigue and adverse events. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
